Titan Biotech Limited has announced significant changes to its board committee composition, effective January 2, 2026. The pharmaceutical company's Board of Directors approved the reconstitution of four key committees during a meeting held on January 2, 2026, appointing two new Independent Directors to strengthen its governance framework.

Key Appointments

The company has appointed Mr. Brijesh Kumar Singh and Mr. Debendra Kumar Sabat as members across all four reconstituted committees. Both individuals join as Independent Directors, bringing additional expertise to the company's governance structure.

Committee Reconstitution Details

Audit Committee

The reconstituted Audit Committee now comprises five members:

Nomination & Remuneration Committee

The committee maintains its five-member structure with the new appointments:

Additional Committee Changes

Corporate Social Responsibility Committee

The CSR Committee now includes five members following the reconstitution, with Mr. Rohit Jain continuing as Chairperson and the two new Independent Directors joining as members alongside existing members Mr. Naresh Kumar Singla and Mr. Abhishek Agarwal.

Stakeholders Relationship Committee

The Stakeholders Relationship Committee has been expanded to six members, maintaining Mr. Rohit Jain as Chairperson while adding the two new Independent Directors to the existing team of Mr. Naresh Kumar Singla, Mr. Suresh Chand Singla, and Mr. Dhairya Madan.

Meeting Details

The board meeting that approved these changes commenced at 2:30 PM and concluded at 3:10 PM on January 2, 2026. The company has communicated these changes to BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring compliance with regulatory requirements for corporate governance disclosures.

Titan Biotech Limited has officially announced the results of its postal ballot process, confirming overwhelming shareholder approval for the proposed 1:5 stock split and memorandum of association alteration. The company submitted the voting results to BSE on December 31, 2025, following the conclusion of remote e-voting on December 30, 2025.

Official Postal Ballot Results

The postal ballot process demonstrated exceptional shareholder support across both resolutions, with the scrutinizer's report confirming the requisite majority:

Corporate Action Details

The approved resolutions encompass two key corporate actions that will reshape the company's equity structure:

Shareholder Category Performance

The voting pattern revealed strong consensus across all shareholder categories:

Promoter and Promoter Group:

• Total Holding: 4,609,525 shares
• Participation Rate: 99.9995%
• Approval Rate: 100% for both resolutions

Public Non-Institutional Shareholders:

• Total Holding: 3,654,175 shares
• Participation Rate: 0.18%
• Approval Rate: Over 99% for both resolutions

Regulatory Compliance Framework

The postal ballot was conducted under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Charanjit Singh submitted the comprehensive voting results and scrutinizer's report to BSE, confirming that both ordinary resolutions were deemed passed on December 30, 2025.

Implementation Timeline

With formal approval secured and regulatory submissions completed, the stock split implementation will proceed according to the previously announced timeline. The subdivision will convert each existing equity share of face value ₹10.00 into five equity shares of face value ₹2.00 each, enhancing liquidity and accessibility for retail investors in the pharmaceutical sector.

The comprehensive voting results and scrutinizer's report are available on the company's website at www.titanbiotechltd.com , providing complete transparency for all stakeholders regarding this significant corporate restructuring initiative.